The Dose-Response Relationship of Rocuronium in Patients Taking Pyridostigmine
Information source: University of Toledo Health Science Campus
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Muscle Relaxants
Phase: Phase 4
Status: Recruiting
Sponsored by: Shashi Bhatt, MD Official(s) and/or principal investigator(s):
Shashi Bhatt, MD, Principal Investigator, Affiliation: University of Toledo Health Science Campus
Overall contact:
Shashi Bhatt, MD, Phone: 419-383-3556, Email: shashi.bhatt@utoledo.edu
Summary
Pyridostigmine is a medication that is used in certain heart rate and blood pressure
conditions. This medication, as a side effect, is known to also cause changes in the
junction between a nerve and muscle. The changes caused at the nerve muscle junction by
pyridostigmine could alter the effect of muscle relaxants (a medication used during surgery
and anesthesia). The investigators are conducting this study to see whether patients taking
pyridostigmine are more or less sensitive to rocuronium (a muscle relaxing medication used
during surgery).
Clinical Details
Official title: The Dose-response Relationship of Rocuronium in Patients Taking Pyridostigmine Preoperatively Compared With Age and Sex Matched Controls
Study design: Observational Model: Case Control, Time Perspective: Prospective
Primary outcome: Dose of the muscle relaxant rocuronium that will lead to 50% decrease in the force of the evoked muscle contraction in patients taking pyridostigmine.
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients who take pyridostigmine for any reason or those who are matched by age, sex
and weight to subjects taking pyridostigmine
- Patients who will be administered rocuronium during elective procedures as standard
clinical care.
Exclusion Criteria:
- Allergy to rocuronium
- Known neuromuscular disorder, patients suffering from myasthenia gravis
- Subjects taking medications known to impact neuromuscular transmission (ex.
gentamicin).
Locations and Contacts
Shashi Bhatt, MD, Phone: 419-383-3556, Email: shashi.bhatt@utoledo.edu
University of Toledo, Health Science Campus, Toledo, Ohio 43614, United States; Recruiting
Shashi Bhatt, MD, Phone: 419-383-3556, Email: shashi.bhatt@utoledo.edu
Shashi Bhatt, MD, Principal Investigator
Additional Information
Starting date: March 2014
Last updated: May 27, 2015
|
